MRK  Merck & Company Inc.




Consumer Durables


Major Pharmaceuticals

Market Cap.


Vuru Grade


Current Price

-0.655 (-1.058%)

Growth Price

Overvalued by 11.09%

Stability Price

Overvalued by 66.49%

Company Metrics

  • P/E 33.607
  • P/S 4.341
  • P/B 3.95
  • EPS 1.823
  • Cash ROIC 12.97%
  • Cash Ratio 0.70
  • Dividend 1.84 / 2.99%
  • Avg. Vol. 10.17M
  • Shares 2.77B
  • Market Cap. 169.41B

Company Description

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company's Pharmaceutical segment provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of bone, respiratory, immunology, dermatology, cardiovascular, ... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Nothing Can Stop Merck & Co., Inc. (MRK) Stock Now - Oct 20, 2016
Shares of pharmaceutical giant Merck & Co., Inc. (NYSE:MRK) have been on a roll lately. MRK stock jumped last week and reached its highest levels over the past year.
Analysts: Merck & Co., Inc. (NYSE:MRK) stock is worth $68 - Review Fortune
Watch List: Merck & Co., Inc. (NYSE:MRK) - Post Registrar
Analyst Coverage That Is Worth Watching: Merck & Co., Inc. (NYSE:MRK), NIKE ...
Review Fortune - 6 hours ago
Merck & Co., Inc. (NYSE:MRK) remained bullish with an increase +0.08% putting the price on the $61.26 per share in current trading session on 10/21/2016.
Analyst Research Summary: Merck & Co., Inc. (NYSE:MRK) - The Independent Republic
Merck & Co. (MRK) Scheduled to Post Earnings on Tuesday - The Cerbat Gem
Merck's Keytruda succeeds in key bladder cancer trial
Reuters - 10 hours ago
Merck & Co Inc said its immunotherapy, Keytruda, helped previously treated patients with advanced bladder cancer live longer in a late-stage study, prompting an independent monitoring panel to recommend stopping the trial early.
Trade of the Day: Buy Merck & Co., Inc. (MRK) ... But Not Yet - Oct 14, 2016
Merck & Co., Inc. (NYSE:MRK) - At one point yesterday, Merck was one of only two stocks of the Dow-30 to be in the black, and at the close MRK led the Dow-30 field, up 1.38%.
Check on Ratings and Recommendations Roundup: Merck & Co., Inc. (NYSE:MRK) - Post Registrar
Jim Cramer Gives His Opinion On Merck And Smith & Wesson
Benzinga - 10 hours ago
On CNBC's Mad Money, Jim Cramer spoke about Merck & Co., Inc. (NYSE: MRK). He thinks that the stock would be trading around $65 or $66 on the good news about its drug Keytruda, if there were no political worries.
Current Merck & Co., Inc. (NYSE:MRK) PT Means Stock Is Worth Almost $82
Review Fortune - Oct 6, 2016
Merck & Co., Inc. (NYSE:MRK) down -0.79% for the past 5 days, is under coverage of 22 analysts who collectively assign a hold rating on stock.
Merck & Co. Inc. (MRK) Shuts Down Florida Facility - Insider Monkey (blog)
How Merck & Co., Inc. Ranks As a Top Analyst Pick (MRK) -
Notable Brokerage Recommendations Merck & Co., Inc. (NYSE:MRK), AT&T Inc. (NYSE:T)
Review Fortune - Oct 11, 2016
Merck & Co., Inc. (NYSE:MRK) remained bullish with an increase +0.18% putting the price on the $63.90 per share in last trading session ended on 10/7/2016.
Worth Watching Stock: Merck & Co., Inc. (NYSE:MRK) - News Oracle
Investor's Alert: Merck & Co., Inc. (NYSE:MRK) - Post Registrar
Aetna Inc (NYSE:AET), Merck & Co., Inc. (NYSE:MRK) Sign Value-Based Partnership
Market Exclusive - Oct 13, 2016
Aetna Inc (NYSE:AET) and Merck & Co., Inc. (NYSE:MRK) have recently entered into a value-based agreement for diabetes drugs Januvia (sitagliptin) and Janumet (sitagliptin plus metformin).
Healthcare Actives: Merck & Co., Inc. (NYSE:MRK), Mylan N.V. (NASDAQ:MYL) - Benchmark Monitor
Calculating the intrinsic value of Merck & Co Inc (MRK)
Simply Wall St - 15 hours ago
How far off is Merck (NYSE:MRK) to its intrinsic value? I am going to take a look now by estimating the Future Cash Flows and discounting them to their present value.
Merck Announces Pivotal Phase 3 Study of Letermovir, an Investigational ...
Business Wire (press release) - Oct 19, 2016
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 clinical study of letermovir, an investigational antiviral medicine, met its primary ...
Merck's antiviral drug meets main goal in late-stage trial - Reuters